Authorized purpose: Provide quantitative volumetric liver fat fraction, proton-density fat fraction, and steatosis grading to support clinical diagnosis and subsequent management decisions for confirmed or suspected fatty liver disease or metabolic syndromes and to aid living-donor liver-transplant assessment and screening, with results interpreted by a trained physician.
Clinical role
Post-acquisition MRI protocol-quality checking and automated liver ROI/image analysis followed by report review in clinical context.
Images and patients
MRI · Liver
Key limitation
Keep in mind: The specified MRI protocol and protocol-quality checks are critical to the reported results, and the FDA validation included an excessive-iron assessment that rejected one repeatability case and caused 281 of 300 validation subjects to pass the IQC rules. Results require trained-physician interpretation and clinical context; the packet does not establish unrestricted MRI-sequence or population performance.
Clinical detailsPurpose, workflow fit, evidence, and safety record
Workflow navigation pilot
Workflow role has not yet been reviewed for this navigation pilot.
A tag identifies a documented role; it does not establish compatibility or local acceptance. Methods and sources
What does this software do?Authorized purpose: Provide quantitative volumetric liver fat fraction, proton-density fat fraction, and steatosis grading to support clinical diagnosis and subsequent management decisions for confirmed or suspected fatty liver disease or metabolic syndromes and to aid living-donor liver-transplant assessment and screening, with results interpreted by a trained physician.
Which images or clinical context are in scope?Modality: MRI Anatomy or clinical context: Liver Input: DICOM MRI datasets acquired according to the HepaFatSmart/HepaFat-Scan protocol using the specified gradient-recalled-echo approach, for patients of all populations independent of age and gender with suspected clinical conditions related to liver fat.
Who uses it?Intended users: Trained physicians; the FDA report requires physician interpretation and includes radiologist review of the liver ROI and result.
What does the software produce?Output: PDF and DICOM secondary-capture reports containing VLFF, PDFF, steatosis grade, associated confidence intervals and normal range, two echo-time images, a predicted liver ROI overlay, and a fat-distribution map; Alpha is converted into the reported VLFF, PDFF, and steatosis grade.
What is its most important limitation?Key limitation: The specified MRI protocol and protocol-quality checks are critical to the reported results, and the FDA validation included an excessive-iron assessment that rejected one repeatability case and caused 281 of 300 validation subjects to pass the IQC rules. Results require trained-physician interpretation and clinical context; the packet does not establish unrestricted MRI-sequence or population performance.
Clinical takeaway. Clinical role: Provide quantitative volumetric liver fat fraction, proton-density fat fraction, and steatosis grading to support clinical diagnosis and subsequent management decisions for confirmed or suspected fatty liver disease or metabolic syndromes and to aid living-donor liver-transplant assessment and screening, with results interpreted by a trained physician.
Evidence takeaway. Evidence from the reviewed source record: The FDA packet reports a repeatability study of 42 paired subjects, with 41 used for HepaFatSmart after one high-iron case was rejected, and a validation study of 300 subjects in which 281 passed IQC. For VLFF values above 4.1%, sensitivity was 100.0% (95% CI 97.3%-100.0%) and specificity 98.6% (94.9%-99.6%); above 12.1%, sensitivity 98.8% (93.6%-99.8%) and specificity 98.0% (94.9%-99.2%); above 16.2%, sensitivity 100.0% (93.8%-100.0%) and specificity 99.6% (97.5%-99.9%). Bland-Altman bias, limits of agreement, and repeatability coefficients are separate quantitative-agreement endpoints.
Evidence context
Evidence context not reviewed for this FDA record.
Public-label constraints
Label constraints have not been reviewed for this exact FDA record. Unknown is not all ages or evidence of unsuitability.
Public-label constraints, not patient-level eligibility or a medical recommendation. Training and evaluation populations are separate. Read the original labeling and confirm the exact release and protocol.
Purpose
Provide quantitative volumetric liver fat fraction, proton-density fat fraction, and steatosis grading to support clinical diagnosis and subsequent management decisions for confirmed or suspected fatty liver disease or metabolic syndromes and to aid living-donor liver-transplant assessment and screening, with results interpreted by a trained physician.
DICOM MRI datasets acquired according to the HepaFatSmart/HepaFat-Scan protocol using the specified gradient-recalled-echo approach, for patients of all populations independent of age and gender with suspected clinical conditions related to liver fat.
PDF and DICOM secondary-capture reports containing VLFF, PDFF, steatosis grade, associated confidence intervals and normal range, two echo-time images, a predicted liver ROI overlay, and a fat-distribution map; Alpha is converted into the reported VLFF, PDFF, and steatosis grade.
Clinical liver MRI workflow for suspected or confirmed fatty liver conditions, metabolic syndromes, lifestyle-management support, and living-donor screening; the FDA packet does not specify a facility type.
The specified MRI protocol and protocol-quality checks are critical to the reported results, and the FDA validation included an excessive-iron assessment that rejected one repeatability case and caused 281 of 300 validation subjects to pass the IQC rules. Results require trained-physician interpretation and clinical context; the packet does not establish unrestricted MRI-sequence or population performance.
The FDA packet reports a repeatability study of 42 paired subjects, with 41 used for HepaFatSmart after one high-iron case was rejected, and a validation study of 300 subjects in which 281 passed IQC. For VLFF values above 4.1%, sensitivity was 100.0% (95% CI 97.3%-100.0%) and specificity 98.6% (94.9%-99.6%); above 12.1%, sensitivity 98.8% (93.6%-99.8%) and specificity 98.0% (94.9%-99.2%); above 16.2%, sensitivity 100.0% (93.8%-100.0%) and specificity 99.6% (97.5%-99.9%). Bland-Altman bias, limits of agreement, and repeatability coefficients are separate quantitative-agreement endpoints.
Metrics are shown only when they are tied to a source, endpoint, population, and tested product version. Candidate literature without exact product and version linkage is not shown as product evidence.
Evidence summary
The FDA packet reports a repeatability study of 42 paired subjects, with 41 used for HepaFatSmart after one high-iron case was rejected, and a validation study of 300 subjects in which 281 passed IQC. For VLFF values above 4.1%, sensitivity was 100.0% (95% CI 97.3%-100.0%) and specificity 98.6% (94.9%-99.6%); above 12.1%, sensitivity 98.8% (93.6%-99.8%) and specificity 98.0% (94.9%-99.2%); above 16.2%, sensitivity 100.0% (93.8%-100.0%) and specificity 99.6% (97.5%-99.9%). Bland-Altman bias, limits of agreement, and repeatability coefficients are separate quantitative-agreement endpoints.
FDA VLFF-threshold sensitivity in the IQC-passing validation set (n=281): VLFF >4.1% 100.0% (95% CI 97.3%-100.0%); VLFF >12.1% 98.8% (93.6%-99.8%); VLFF >16.2% 100.0% (93.8%-100.0%).
FDA source
Exact FDA submission
Checked 2026-09-09
The FDA values are threshold-specific sensitivity for predicting HepaFat-Scan VLFF values, not a generic 90% device metric or a clinical-outcome endpoint.
FDA VLFF-threshold specificity in the IQC-passing validation set (n=281): VLFF >4.1% 98.6% (95% CI 94.9%-99.6%); VLFF >12.1% 98.0% (94.9%-99.2%); VLFF >16.2% 99.6% (97.5%-99.9%).
FDA source
Exact FDA submission
Checked 2026-09-09
The FDA values are threshold-specific specificity for predicting HepaFat-Scan VLFF values; Bland-Altman and repeatability results remain separate.
No contextualized exact-version metric has completed evidence review. Regulatory-document values, when available, are shown above with their limitations.
HepaFatSmart (V2.0.0) regulatory performance study summary
DesignStand-Alone Performance
PopulationAdult and Pediatric
Scopeexact submission
Tested versionExact product version not reported; regulatory study summarized for FDA submission K231459
Samplen=300
IndependenceIndependence not established
K231459
ACR AI Central summarizes the regulatory study; consult the exact FDA materials before comparative use.
Recall and adverse-event records are shown only after product matching. Adverse-event reports do not establish incidence or causality.
Postmarket safety review
The exact-identifier FDA recall query returned no native recall record for K231459. This limited result does not establish absence of recalls or other safety information and does not cover later versions, family records, MAUDE reports, corrections, or field notices.
IT implementationDeployment, interfaces, data handling, and support
System and version relationships
Match the AI release, system build, configuration and region. Source documentation does not establish acceptance of an installed system.
No specific system/version pairing has completed review for this FDA record. A broad DICOM or product-family statement does not establish a named viewer build's support.
Public source context, not tested interoperability. Each hop needs its own release/configuration evidence. Missing or unavailable routes are not documented incompatibility. All local tests are planned, not passed; no installed-system acceptance is recorded.
Acquisition/source → routing → AI processing → returned objects → viewer/worklist/report → support owner
No specific route context has been source-reviewed for this record. Obtain both endpoint builds and documents; this is not a finding of incompatibility.
Acquisition/source
Source context, not route validation: DICOM MRI datasets acquired according to the HepaFatSmart/HepaFat-Scan protocol using the specified gradient-recalled-echo approach, for patients of all populations independent of age and gender with suspected clinical conditions related to liver fat.
Scope: Exact FDA submission.
Confirm scanner/model, protocol, series completeness and both software builds.
Source context, not route validation: The FDA description states that users upload DICOM images to the FAST portal/job-management system and that HepaFatSmart can be accessed through cloud-based, onsite, or third-party platforms, with PDF and DICOM secondary-capture reports; exact current interfaces, hosting configuration, and local compatibility are not established.
Scope: Exact FDA submission.
Name gateways, destinations, transfer rules and failure visibility; a DICOM statement does not prove a route.
Source context, not route validation: The exact FDA package describes HepaFatSmart as accessed through a cloud-based or onsite platform, including Resonance Health's own cloud-based platform called FAST, or offered on third-party (channel partner) platforms. Current hosting, data flow, and commercial configuration require vendor confirmation.
Scope: Exact FDA submission. Packet wording: "HepaFatSmart SaMD can be accessed through a cloud-based or onsite platform. Resonance Health has developed its own cloud-based platform, called ‘FAST’." … "Alternatively, HepaFatSmart can be offered on third parties’ (channel partner) platforms.". Read from the exact FDA decision document on 2026-11-14; this is the release-level description, not current commercial configuration.
Confirm processing location, queue ownership, exclusions and exact AI build.
Source context, not route validation: PDF and DICOM secondary-capture reports containing VLFF, PDFF, steatosis grade, associated confidence intervals and normal range, two echo-time images, a predicted liver ROI overlay, and a fat-distribution map; Alpha is converted into the reported VLFF, PDFF, and steatosis grade.
Scope: Exact FDA submission.
Confirm object classes, units, references and whether findings, overlays or measurements reach their intended destination.
Unresolved route: PDF and DICOM secondary-capture reports containing VLFF, PDFF, steatosis grade, associated confidence intervals and normal range, two echo-time images, a predicted liver ROI overlay, and a fat-distribution map; Alpha is converted into the reported VLFF, PDFF, and steatosis grade.
Scope: Exact FDA submission.
Confirm the named viewer/worklist/report build, display behavior and report transfer. Output support alone does not establish this endpoint. The displayed source describes output, not validated end-to-end delivery.
Unresolved route: Not established for the exact route.
Scope: Scope not established.
Name the local, platform and AI supplier support owners and escalation path.
Planned local route tests
No tests below have been performed or accepted.
Patient/study identity (planned). Use approved non-patient test data to verify identifiers, accession and result-to-study linkage at every hop.
Study completeness (planned). Test missing views/series, partial transfer, late arrivals, priors and unsupported acquisition inputs; confirm explicit refusal or fallback.
Ordering and duplicates (planned). Send out-of-order, repeated and corrected studies; verify worklist order, deduplication and no misleading stale results.
Report transfer (planned). Verify output object types, annotations, units, report content, destination and availability of original images.
Access (planned). Verify authorized roles, audit trail, denied access and support ownership at each destination.
Latency and failures (planned). Agree a workload and turnaround target; test queues, timeouts, missing results and fallback reading.
Updates and rollback (planned). Define version change control, revalidation triggers, stop-use criteria and a tested rollback route.
Local implementation checklist
Agree the evidence and acceptance owner with your team and suppliers. Checkmarks apply to this page only and are not acceptance receipts.
The exact FDA package describes HepaFatSmart as accessed through a cloud-based or onsite platform, including Resonance Health's own cloud-based platform called FAST, or offered on third-party (channel partner) platforms. Current hosting, data flow, and commercial configuration require vendor confirmation.
Exact FDA submission
Checked 2026-11-14
Packet wording: "HepaFatSmart SaMD can be accessed through a cloud-based or onsite platform. Resonance Health has developed its own cloud-based platform, called ‘FAST’." … "Alternatively, HepaFatSmart can be offered on third parties’ (channel partner) platforms.". Read from the exact FDA decision document on 2026-11-14; this is the release-level description, not current commercial configuration.
The FDA description states that users upload DICOM images to the FAST portal/job-management system and that HepaFatSmart can be accessed through cloud-based, onsite, or third-party platforms, with PDF and DICOM secondary-capture reports; exact current interfaces, hosting configuration, and local compatibility are not established.
ACR AI Central provides an exact-submission model card for HepaFatSmart (V2.0.0); FDA labeling remains controlling for clinical use, limitations, and performance.
Sources & review detailsFDA identity, research record, source ledger, and history
Regulatory identity
FDA record and catalog context
The FDA listing establishes the regulatory identity. It does not by itself establish local workflow fit, pricing, security, or performance in your environment.
This audit distinguishes completed source review from fields that have not yet been researched.
Exact FDA record reviewedStatus
2026-09-20Last searched
26Fields reviewed
9Source classes checked
0Screened PubMed leads
0Screened trial leads
0Unreviewed FDA recall leads
The refreshed discovery snapshot contains no PubMed or ClinicalTrials.gov candidates; no external evidence was promoted. The current discovery snapshot contains 0 PubMed and 0 ClinicalTrials.gov candidate records; its dated, count-matched human screening remains current. Unlinked candidates remain quarantined. Native FDA recall identifiers produced 0 postmarket candidate records; 0 have been reviewed (0 published, 0 rejected) and 0 remain unreviewed.
Candidate leads were screened against the exact product and tested version. Unlinked records remain quarantined.
Source classes: fda ai list, fda decision summary, acr ai central product, fda device recall, literature index, trial registry, pubmed, clinical trials, openfda device recall
Field review details
Recorded state, verification date, notes and sources for fields without a publishable value. Conflicting records stay explicitly unsettled here; no plain settled value is shown for them.
Public pricing: Not verified - checked 2026-09-09 - Exact FDA submission
No public price or quote for the exact K231459 configuration was established in this review.
Pricing model: Not yet reviewed
Setup and integration fees: Not yet reviewed
Recurring fees: Not yet reviewed
Minimum commitment: Not yet reviewed
Contract duration: Not yet reviewed
Renewal terms: Not yet reviewed
Cancellation terms: Not yet reviewed
Support and service terms: Not yet reviewed
Trial or pilot terms: Not yet reviewed
Reimbursement: Not publicly available - checked 2026-09-09 - Exact FDA submission
No exact-product payer policy, coding instruction, or payment determination was established; eligibility must be evaluated by payer, site of service, and use case.
Data hosting location: Not yet reviewed
Data retention: Not yet reviewed
Documented data use: Not yet reviewed
Hardware requirements: Not yet reviewed
Network requirements: Not yet reviewed
Identity and access: Not yet reviewed
Security: Not verified - checked 2026-09-09 - Exact FDA submission
Exact-release security controls, data retention, hosting boundaries, and scoped assurance documentation require vendor confirmation.
Installation timeline: Not yet reviewed
Training: Not verified - checked 2026-09-09 - Exact FDA submission
Current training prerequisites, competency checks, and support commitments for the exact configuration require vendor confirmation.
Monitoring: Not verified - checked 2026-09-09 - Exact FDA submission
Current drift, quality, uptime, alert, escalation, and incident-response commitments for the exact configuration require vendor confirmation.
Authorized purpose: LiverMultiScan v6.0 is MR diagnostic software for non-invasive liver-health assessment that generates, displays, and supports review of MR data and quantitative cT1, PDFF, and LIC metrics or composite images for trained healthcare-professional interpretation.
Authorized purpose: LiverMultiScan v5 (LMSv5) is indicated for use as a magnetic resonance diagnostic device software application for noninvasive liver evaluation that enables the generation, display and review of 2D magnetic resonance medical image data and pixel maps for MR relaxation times.LMSv5 is designed to utilize DICOM 3.0 compliant magnetic resonance image datasets, acquired from compatible MRSystems, to display the internal structure of the abdomen including the liver. Other physical parameters derived from the images may also be produced.LMSv5 provides several tools, such as automated liver segmentation and region of interest (ROI) placements, to be used for the assessment of selected regions of an image. Quantitative assessment of selected regions includes the determination of triglyceride fat fraction in the liver (PDFF), T2*, LIC (Liver Iron Concentration) and iron corrected T1(cT1) measurements. These images and the physical parameters derived from the images, when interpreted by a trained clinician, yield information that may assist in diagnosis.
Authorized purpose: Measures liver iron concentration for specified iron-overload and thalassemia/sickle-cell indications; assesses VLFF, PDFF, and steatosis grade for suspected or confirmed fatty liver disease; physician-interpreted results may support weight-loss monitoring and living-donor assessment.
Authorized purpose: Hepatica (Hepatica v1) is a post-processing medical device software that presents quantified metrics which may contribute to the assessment of a patient's liver health. Hepatica (Hepatica v1) uses image visualization and analysis tools to process DICOM 3.0 compliant magnetic resonance image datasets to produce semi-automatic segmented 3D models of the liver based on the work of Couinaud and the Brisbane 2000 terminology. For each identified Couinaud segment, volumetric data is determined and reported. Hepatica (Hepatica v1) may also report iron corrected-T1 (cT1) and PDFF calculated using the IDEAL method from multi-slice acquisitions, on a per segment basis, over the whole liver. Both metrics present numerical values of different fundamental liver tissue characteristics that can be used as measures of liver tissue health. Hepatica (Hepatica v1) provides trained clinicians with additional information to evaluate the volume and health of patient's liver on a segmental basis. It is not intended to replace the established procedures for the assessment of patient's liver health. However, information gathered through existing diagnostic tests, clinical evaluation of the patient, as well Hepatica (Hepatica v1), may support surgical decision making.
Copy this public context and add the field, proposed wording and original source before sending. Nothing here is submitted automatically. Form-specific prefill has not been verified.
Permission to display a submission is not evidence verification. A submission enters editorial review; it does not approve a public change. Form availability, data entry, receipt, review and publication are separate steps. Data entry and receipt remain unverified.
Accepted repository change history
No entry has been added to this scoped change history for this record. This is not proof that the record never changed.